Abstract
Objective To assess the insulin-like growth factor-1 receptor (IGF1R) expression in urothelial carcinoma (UC) and its prognostic role in relation to clinicopathologic parameters. Methods A total of 100 cases of invasive UC were evaluated using tissue microarrays. Membranous IGF1R staining was evaluated using immunohistochemistry. A scoring method analogous to that of HER2 expression in breast carcinoma was used, and the highest score was assigned in each tumor. IGF1R was considered overexpressed in cases with score ≥1. Results We found IGF1R overexpression in 62% of invasive UC. IGF1R overexpression was associated with race (P =.04) and pT category (P =.03). Median follow-up was 29 months (range, 0.5-212). Progression rate was 60%, and overall mortality and cancer-specific mortality rates were 69% and 51%, respectively. In invasive UC, IGF1R overexpression was significantly associated with overall mortality and cancer-specific mortality (Mantel Cox P =.0002 and P =.006, respectively). IGF1R overexpression was associated with increased hazard ratios (HRs) for overall mortality (HR = 2.63, P =.001) and cancer-specific mortality (HR = 2.45, P =.01), independently and after adjusting for clinicopathologic features and treatment modalities. Conclusion We found IGF1R overexpression in 62% of bladder UC. More importantly, IGF1R overexpression was a significant predictor of overall mortality and cancer-specific mortality, suggesting its potential role as a prognosticator in UC of bladder.
| Original language | English (US) |
|---|---|
| Journal | Urology |
| Volume | 83 |
| Issue number | 6 |
| DOIs | |
| State | Published - 2014 |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder : A retrospective study of patients treated using radical cystectomy. / Gonzalez-Roibon, Nilda; Kim, Jenny J.; Faraj, Sheila F.; Chaux, Alcides; Bezerra, Stephania M.; Munari, Enrico; Ellis, Carla; Sharma, Rajni; Keizman, Daniel; Bivalacqua, Trinity; Schoenberg, Mark; Eisenberger, Mario; Carducci, Michael A; Netto, George J.
In: Urology, Vol. 83, No. 6, 2014.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder
T2 - A retrospective study of patients treated using radical cystectomy
AU - Gonzalez-Roibon, Nilda
AU - Kim, Jenny J.
AU - Faraj, Sheila F.
AU - Chaux, Alcides
AU - Bezerra, Stephania M.
AU - Munari, Enrico
AU - Ellis, Carla
AU - Sharma, Rajni
AU - Keizman, Daniel
AU - Bivalacqua, Trinity
AU - Schoenberg, Mark
AU - Eisenberger, Mario
AU - Carducci, Michael A
AU - Netto, George J.
PY - 2014
Y1 - 2014
N2 - Objective To assess the insulin-like growth factor-1 receptor (IGF1R) expression in urothelial carcinoma (UC) and its prognostic role in relation to clinicopathologic parameters. Methods A total of 100 cases of invasive UC were evaluated using tissue microarrays. Membranous IGF1R staining was evaluated using immunohistochemistry. A scoring method analogous to that of HER2 expression in breast carcinoma was used, and the highest score was assigned in each tumor. IGF1R was considered overexpressed in cases with score ≥1. Results We found IGF1R overexpression in 62% of invasive UC. IGF1R overexpression was associated with race (P =.04) and pT category (P =.03). Median follow-up was 29 months (range, 0.5-212). Progression rate was 60%, and overall mortality and cancer-specific mortality rates were 69% and 51%, respectively. In invasive UC, IGF1R overexpression was significantly associated with overall mortality and cancer-specific mortality (Mantel Cox P =.0002 and P =.006, respectively). IGF1R overexpression was associated with increased hazard ratios (HRs) for overall mortality (HR = 2.63, P =.001) and cancer-specific mortality (HR = 2.45, P =.01), independently and after adjusting for clinicopathologic features and treatment modalities. Conclusion We found IGF1R overexpression in 62% of bladder UC. More importantly, IGF1R overexpression was a significant predictor of overall mortality and cancer-specific mortality, suggesting its potential role as a prognosticator in UC of bladder.
AB - Objective To assess the insulin-like growth factor-1 receptor (IGF1R) expression in urothelial carcinoma (UC) and its prognostic role in relation to clinicopathologic parameters. Methods A total of 100 cases of invasive UC were evaluated using tissue microarrays. Membranous IGF1R staining was evaluated using immunohistochemistry. A scoring method analogous to that of HER2 expression in breast carcinoma was used, and the highest score was assigned in each tumor. IGF1R was considered overexpressed in cases with score ≥1. Results We found IGF1R overexpression in 62% of invasive UC. IGF1R overexpression was associated with race (P =.04) and pT category (P =.03). Median follow-up was 29 months (range, 0.5-212). Progression rate was 60%, and overall mortality and cancer-specific mortality rates were 69% and 51%, respectively. In invasive UC, IGF1R overexpression was significantly associated with overall mortality and cancer-specific mortality (Mantel Cox P =.0002 and P =.006, respectively). IGF1R overexpression was associated with increased hazard ratios (HRs) for overall mortality (HR = 2.63, P =.001) and cancer-specific mortality (HR = 2.45, P =.01), independently and after adjusting for clinicopathologic features and treatment modalities. Conclusion We found IGF1R overexpression in 62% of bladder UC. More importantly, IGF1R overexpression was a significant predictor of overall mortality and cancer-specific mortality, suggesting its potential role as a prognosticator in UC of bladder.
UR - http://www.scopus.com/inward/record.url?scp=84901604277&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901604277&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2014.01.028
DO - 10.1016/j.urology.2014.01.028
M3 - Article
C2 - 24713135
AN - SCOPUS:84901604277
VL - 83
JO - Urology
JF - Urology
SN - 0090-4295
IS - 6
ER -